| 11261237 |
Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection |
Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio |
2022-03-01 |
$214,119,000 |
| 11207423 |
Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs |
Ignacio Melgar-Asensio |
2021-12-28 |
|
| 10583199 |
Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs |
Ignacio Melgar-Asensio |
2020-03-10 |
|
| 10081668 |
Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection |
Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio |
2018-09-25 |
|
| 7491718 |
Sulfonamides having antiangiogenic and anticancer activity |
Kenneth Comess, Scott A. Erickson, Douglas M. Kalvin, Megumi Kawai, Ki Kim +13 more |
2009-02-17 |
$139,792,000 |
| 7432245 |
Pharmaceutical formulation comprising a peptide angiogenesis inhibitor |
Fortuna Haviv, Bryan K. Erickson, Luk-Chiu Li, Fanfeng Ma, Friedrich Richter +3 more |
2008-10-07 |
$110,217,000 |
| 7030262 |
3-Amino-2-hydroxyalkanoic acids and their prodrugs |
Nwe BaMaung, Richard A. Craig, Megumi Kawai, Xenia B. Searle, George S. Sheppard +1 more |
2006-04-18 |
$69,029,000 |
| 6849757 |
Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Megumi Kawai, George S. Sheppard, Richard A. Craig |
2005-02-01 |
$149,451,000 |
| 6777535 |
N-alkylated peptides having antiangiogenic activity |
Fortuna Haviv, Douglas M. Kalvin, Michael Bradley |
2004-08-17 |
$57,458,000 |
| 6774211 |
Peptide antiangiogenic drugs |
Fortuna Haviv, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-08-10 |
$59,696,000 |
| 6753408 |
Peptides having antiangiogenic activity |
Fortuna Haviv, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-06-22 |
|
| 6716963 |
Peptide antiangiogenic drugs |
Fortuna Haviv, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-04-06 |
$72,847,000 |
| 6632961 |
Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Megumi Kawai, George S. Sheppard, Richard A. Craig |
2003-10-14 |
$123,929,000 |
| 6288228 |
Triazine angiogenesis inhibitors |
Donald J. Davidson, George S. Sheppard, Keith W. Woods, Richard W. McCroskey |
2001-09-11 |
|
| 6242494 |
Substituted .beta.-amino acid inhibitors of methionine aminopeptidase-2 |
Richard A. Craig, Megumi Kawai, Linda Lynch, Jyoti R. Patel, George S. Sheppard +1 more |
2001-06-05 |
$106,257,000 |
| 6150362 |
Triazine angiogenesis inhibitors |
Donald J. Davidson |
2000-11-21 |
|
| 5932545 |
Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Noel P. Bouck, David W. Dawson, Andrew J. Schneider |
1999-08-03 |
$55,582,000 |
